{# max-image-preview:large is what makes an article eligible for the big-image card in Google Discover — without it Google may only show a thumbnail. #} {# ── Google Preferred Sources ──────────────────────────────────────────── Readers who mark us as a preferred source get our fresh articles prioritised in Top Stories, Discover and Google News. Only domain- and subdomain-level sites are eligible — blog.alfafinder.com qualifies, a /news/ subdirectory would not. #}

Emcure Pharmaceuticals — Latest News

Every announcement Emcure Pharmaceuticals has filed with the exchanges that we have reported, newest first. Each story links the original filing.

NSE: EMCURE BSE: 544210 Pharmaceuticals & Biotechnology 2 stories

Price

₹1678

Market Cap

₹31,813.12 Cr

Revenue TTM

₹9,203.54 Cr

P/E (TTM)

34.42×

Sector 41.56×

Reference data from Trendlyne, as of the most recent story. Not a valuation or a recommendation.

Earning Call · 2
Earning Call

Emcure Pharmaceuticals Crosses $1 Billion Revenue Milestone as FY26 PAT Surges 41%

Emcure Pharmaceuticals reports FY26 revenue of ₹9,204 crore, achieving 16.6% YoY growth and surpassing the $1 billion mark with strong international …
Earning Call

Emcure Pharmaceuticals Achieves ₹9,204 Cr Revenue Milestone; Targets Margin Growth in FY27

Emcure Pharmaceuticals reports ₹9,204 Cr revenue for FY26, surpassing the $1 billion mark. Management guides for margin expansion and domestic recove…

Track Emcure Pharmaceuticals in real time

ALFA Finder watches NSE & BSE filings 24/7 and alerts you the moment Emcure Pharmaceuticals files something material.

Start Free — 15-day trial
{# ── Promo popup — fires 5s after first page load per session. NEVER fires for visitors arriving from a search engine: a full-viewport overlay on a news article is an intrusive interstitial, and Google News policy is explicit that promotional material must not exceed the content. Direct, social and referral traffic still sees it. ─────────── #}